Medicilon assists Shijiazhuang No.4 Pharmaceutical's Class 1 new chemical drug SYN045 tablets obtain clinical approval
On January 26, SYN045, a Class I new drug developed by Shijiazhuang No.4 Pharmaceutical, received a clinical trial approval notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This marks another substantial step forward in the research and development of the company's second innovative drug. Shanghai Medicilon Inc. (Medicilon), as a partner of Shijiazhuang No.4 Pharmaceutical, provided preclinical research services such as pharmacokinetics and safety evaluation for the development of SYN045 tablets, helping to successfully obtain approval. SYN045 is a Class I new drug independently developed by Shijiazhuang No.4 Pharmaceutical. SYN045 is a selective long-acting PGI2 receptor agonist and is intended to be used for pulmonary arterial hypertension. Preclinical studies have shown that SYN045 has good target selectivity, compound activity, and safety. Currently, Medicilon's preclinical research service platform has...